Navigation Links
Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Date:10/25/2011

NEW YORK, Oct. 25, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661235/Pneumonia-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global pneumonia therapeutics market, identifying the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global pneumonia therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimated the pneumonia therapeutics market to be worth $1,988m in 2010. It is forecast to decline at a Compound Annual Growth Rate (CAGR) of 1.1% to reach $1,815m by 2018. The market deteriorated during 2005-2010 owing to the patent expiries of major drugs such as Zithromax (azithromycin), Zosyn (piperacillin-tazobactam) and Levaquin (levofloxacin) in 2005, 2007 and 2010 respectively. The decline during the forecast period can be attributed to the expected patent expiry of Avelox (moxifloxacin), Tygacil (tigecycline) in 2014 and 2016 respectively. Zyvox (linezolid) will also lose its patent protection in 2015 in the US and 2016 in Europe and Japan. The late stage pipeline lacks molecules that act against antibiotic-resistant bacterial strains and is therefore unlikely to have a significant impact on the market.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the pneumonia therapeutics market. Its scope includes -

- Annual data on the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) for pneumonia therapeutics, with historic data from 2005 to 2010 and forecasts to 2018.

- Pipeline analysis data providing information on the different phases of development, mechanisms of action and emerging trends. Pipeline candidates for pneumonia fall under major therapeutic classes as immunomodulators, penicillin-binding proteins (PBPs) inhibitor, and ribosomal 50S subunit inhibitor.

- Analysis of the current and future competition in the global pneumonia therapeutics market is provided. The key market players covered are Pfizer and Basilea Pharmaceutica Ltd.

- An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics coverage, including strategic a competitor assessment, market characterization and unmet needs analysis, as well as their implications for the pneumonia therapeutics market.

- Analysis of key recent licensing and partnership agreements in the pneumonia therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.

- Develop business strategies by understanding the trends shaping and driving the global pneumonia therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global pneumonia therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global pneumonia therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Pneumonia Therapeutics: Executive Summary 9

2.1 The Pneumonia Therapeutics Market is Forecast to Decline Until 2018 9

2.2 The Pneumonia Therapeutics Market has Low Unmet Need with Low Potential for New Entrants 10

2.3 Delay in the Approval of Antibacterial Drugs 11

3 Pneumonia Therapeutics: Introduction 12

3.1 Overview 12

3.2 Community-Acquired Pneumonia (CAP) 13

3.2.1 Etiology of CAP 13

3.2.2 Epidemiology of CAP 14

3.2.3 Diagnosis of CAP 14

3.2.4 Treatment of CAP 16

3.3 Healthcare-Associated Pneumonia (HCAP) 18

3.3.1 Etiology of HCAP 19

3.3.2 Epidemiology of HCAP 19

3.3.3 Diagnosis of HCAP 19

3.3.4 Treatment of HCAP 20

3.4 GlobalData Pipeline Report Guidance 22

4 Pneumonia Therapeutics: Market Characterization 23

4.1 Pneumonia Therapeutics Market Size (2005–2010) – Global 23

4.2 Pneumonia Therapeutics Market Forecast (2010–2018) – Global 25

4.3 Pneumonia Therapeutics Market Size (2005–2010) – The US 26

4.4 Pneumonia Therapeutics Market Forecast (2010–2018) – The US 28

4.5 Pneumonia Therapeutics Market Forecast (2005-2010) – The UK 29

4.6 Pneumonia Therapeutics Market Forecast (2010-2018) – The UK 31

4.7 Pneumonia Therapeutics Market Size (2005-2010) – France 32

4.8 Pneumonia Therapeutics Market Size (2010-2018) – France 34

4.9 Pneumonia Therapeutics Market Size (2005-2010) – Germany 35

4.10 Pneumonia Therapeutics Market Forecast (2010-2018) – Germany 37

4.11 Pneumonia Therapeutics Market Size (2005-2010) – Italy 38

4.12 Pneumonia Therapeutics Market Forecast (2010-2018) – Italy 40

4.13 Pneumonia Therapeutics Market Size (2005-2010) – Spain 41

4.14 Pneumonia Therapeutics Market Forecast (2010-2018) – Spain 43

4.15 Pneumonia Therapeutics Market Size (2005-2010) – Japan 44

4.16 Pneumonia Therapeutics Market Forecast (2010-2018) – Japan 46

4.17 Drivers and Barriers for the Pneumonia Therapeutics Market 47

4.17.1 Drivers for the Pneumonia Therapeutics Market 47

4.17.2 Barriers for the Pneumonia Therapeutics Market 47

4.18 Key Events Impacting the Future Market 48

4.19 Opportunity and Unmet Need 48

4.20 Key Takeaway 51

5 Pneumonia Therapeutics Market: Competitive Assessment 52

5.1 Overview 52

5.1.1 Strategic Competitor Assessment 52

5.2 Product Profiles for the Major Marketed Products in the Pneumonia Therapeutics Market 54

5.2.1 Avelox (moxifloxacin) 54

5.2.2 Biaxin (clarithromycin) 55

5.2.3 Doribax (doripenem) 56

5.2.4 Levaquin (levofloxacin) 57

5.2.5 Tygacil (tigecycline) 57

5.2.6 Zithromax (azithromycin) 58

5.2.7 Zosyn (piperacillin and tazobactam) 59

5.2.8 Zyvox (linezolid) 60

5.2.9 Zinforo (ceftaroline fosamil) 61

6 Pneumonia Therapeutics Market: Pipeline Assessment 62

6.1 Overview 62

6.2 Strategic Pipeline Assessment 62

6.3 Pneumonia Therapeutics Pipeline Analysis – Pipeline by Clinical Phases of Development 63

6.3.1 Pneumonia Therapeutics – Pre-Registration 63

6.3.2 Pneumonia Therapeutics – Phase III Pipeline 64

6.3.3 Pneumonia Therapeutics – Phase II Pipeline 64

6.3.4 Pneumonia Therapeutics – Phase I/II Pipeline 65

6.3.5 Pneumonia Therapeutics – Phase I Pipeline 66

6.3.6 Pneumonia Therapeutics – Pre-Clinical Pipeline 66

6.4 Pneumonia Therapeutics Market – Clinical Pipeline by Mechanism of Action 66

6.5 Pneumonia Therapeutics Technology Trends Analytical Framework 68

6.6 Pneumonia Therapeutics – Promising Drugs under Clinical Development 70

6.7 Molecule Profile for Promising Drugs under Clinical Development 71

6.7.1 Ceftobiprole medocaril (BAL5788) 71

6.7.2 Tritanrix HepB (GSK Biologicals' Haemophilus influenzae Type b Vaccine) 72

6.7.3 Prevnar 13 (PCV13) 72

7 Pneumonia Therapeutics – Clinical Trials Mapping 74

7.1 Clinical Trials by Country 74

7.2 Clinical Trials by Phase 75

7.3 Clinical Trials by Trial Status 77

7.4 Overall Sponsors 78

7.5 Prominent Sponsors 80

7.6 Top Companies Participating in Pneumonia Therapeutics Clinical Trials 81

8 Pneumonia Therapeutics: Strategic Assessment 84

8.1 Future Market Competition Scenario 84

9 Pneumonia Therapeutics: Future Players in The Market 86

9.1 Introduction 86

9.2 Company Profiles 87

9.2.1 Basilea Pharmaceutica Ltd. 87

9.2.2 Pfizer Inc. 87

9.2.3 Other Companies in the Pneumonia Therapeutics Market 90

10 Pneumonia Therapeutics: Licensing and Partnership Deals 93

11 Pneumonia Therapeutics: Appendix 96

11.1 Definitions 96

11.2 Acronyms 96

11.3 Research Methodology 98

11.3.1 Coverage 98

11.3.2 Secondary Research 98

11.3.3 Forecasting 99

11.3.4 Primary Research 102

11.3.5 Expert Panel Validation 102

11.4 Contact Us 102

11.5 Disclaimer 103

11.6 Bibliography 103

List of Tables

Table 1: Sensitivity and Specificity of Diagnostic Tests for CAP 16

Table 2: Pneumonia Severity Index – Total Score 17

Table 3: Pneumonia Therapeutics Market, Global, Revenue ($m), 2005–2010 25

Table 4: Pneumonia Therapeutics Market, Global, Forecast ($m), 2010–2018 27

Table 5: Pneumonia Therapeutics Market, The US, Revenue ($m), 2005–2010 28

Table 6: Pneumonia Therapeutics Market, The US, Forecast ($m), 2010–2018 30

Table 7: Pneumonia Therapeutics Market, The UK, Revenue ($m), 2005–2010 31

Table 8: Pneumonia Therapeutics Market, The UK, Forecast ($m), 2010–2018 33

Table 9: Pneumonia Therapeutics Market, France, Revenue ($m), 2005–2010 34

Table 10: Pneumonia Therapeutics Market, France, Forecast ($m), 2010–2018 36

Table 11: Pneumonia Therapeutics Market, Germany, Revenue($m), 2005–2010 37

Table 12: Pneumonia Therapeutics Market, Germany, Forecast ($m), 2010–2018 39

Table 13: Pneumonia Therapeutics Market, Italy, Revenue ($m), 2005–2010 40

Table 14: Pneumonia Therapeutics Market, Italy, Forecast ($m), 2010–2018 42

Table 15: Pneumonia Therapeutics Market, Spain, Revenue ($m), 2005–2010 43

Table 16: Pneumonia Therapeutics Market, Spain, Forecast ($m), 2010–2018 45

Table 17: Pneumonia Therapeutics Market, Japan, Revenue ($m), 2005–2010 46

Table 18: Pneumonia Therapeutics Market, Japan, Forecast ($m), 2010–2018 48

Table 19: Pneumonia Therapeutics - Pre-Registration 66

Table 20: Pneumonia Therapeutics - Phase III Pipeline 66

Table 21: Pneumonia Therapeutics - Phase II Pipeline 67

Table 22: Pneumonia Therapeutics - Phase I/II Pipeline 67

Table 23: Pneumonia Therapeutics - Phase I Pipeline 68

Table 24: Pneumonia Therapeutics- Pre-Clinical Pipeline 68

Table 25: Mechanisms of Action that Constitute Others in Figure 30 70

Table 26: Pneumonia Therapeutics – Most Promising Drugs Under Clinical Development, 2011 73

Table 27: Pneumonia Therapeutics – Clinical Trials by Country, 2011 77

Table 28: Pneumonia Therapeutics – Clinical Trials by Phase, 2011 78

Table 29: Pneumonia Therapeutics – Clinical Trials by Status, 2011 80

Table 30: Pneumonia Therapeutics – Prominent Sponsors, 2011 83

Table 31: Pneumonia Therapeutics – Top Companies Participating in Clinical Trials, 2011 85

Table 32: Basilea Pharmaceutica Ltd. – Pneumonia Therapeutics Pipeline 89

Table 33: Pfizer Inc.– Pneumonia Therapeutics Pipeline 92

Table 34: Pneumonia Therapeutics Market – Future Players 93

Table 35: Pneumonia Therapeutics: Licensing and Partnership Deals 95

List of Figures

Figure 1: Pneumonia Therapeutics Market, Global, Revenue and Forecast ($m), 2005-2018 10

Figure 2: Opportunity and Unmet Need – HCAP Segment in Pneumonia Therapeutics 11

Figure 3: Revised Classification of Pneumonia 13

Figure 4: Etiology of CAP 15

Figure 5: Severity Index 18

Figure 6: Management of CAP 19

Figure 7: Diagnosis and Management of HCAP 21

Figure 8: Pneumonia Therapeutics Market, Global, Revenue ($m), 2005–2010 25

Figure 9: Pneumonia Therapeutics Market, Global, Forecast ($m), 2010–2018 26

Figure 10: Pneumonia Therapeutics Market, The US, Revenue ($m), 2005–2010 28

Figure 11: Pneumonia Therapeutics Market, The US, Forecast ($m), 2010–2018 29

Figure 12: Pneumonia Therapeutics Market, The UK, Revenue ($m), 2005–2010 31

Figure 13: Pneumonia Therapeutics Market, The UK, Forecast ($m), 2010–2018 32

Figure 14: Pneumonia Therapeutics Market, France, Revenue ($m), 2005–2010 34

Figure 15: Pneumonia Therapeutics Market, France, Forecast ($m), 2010–2018 35

Figure 16: Pneumonia Therapeutics Market, Germany, Revenue ($m), 2005–2010 37

Figure 17: Pneumonia Therapeutics Market, Germany, Forecast ($m), 2010–2018 38

Figure 18: Pneumonia Therapeutics Market, Italy, Revenue ($m), 2005–2010 40

Figure 19: Pneumonia Therapeutics Market, Italy, Forecast ($m), 2010–2018 41

Figure 20: Pneumonia Therapeutics Market, Spain, Revenue ($m), 2005–2010 43

Figure 21: Pneumonia Therapeutics Market, Spain, Forecast ($m), 2010–2018 44

Figure 22: Pneumonia Therapeutics Market, Japan, Revenue ($m), 2005–2010 46

Figure 23: Pneumonia Therapeutics Market, Japan, Forecast ($m), 2010–2018 47

Figure 24: Pneumonia Therapeutics Market, Drivers and Restraints, 2011 49

Figure 25: Opportunity and Unmet Need – CAP Segment in Pneumonia Therapeutics 51

Figure 26: Opportunity and Unmet Need – HCAP Segment in Pneumonia Therapeutics 52

Figure 27: Pneumonia Therapeutics Market – CAP Treatment ,Strategic Competitor Assessment, 2011 54

Figure 28: Pneumonia Therapeutics Market –HCAP Treatment ,Strategic Competitor Assessment, 2011 55

Figure 29: Pneumonia Therapeutics – Pipeline by Phase of Clinical Development, 2011 65

Figure 30: Pneumonia Therapeutics, Clinical Pipeline by Mechanism Of Action, 2011 69

Figure 31: Pneumonia Therapeutics, Technology Trends Analytics Framework, 2011 71

Figure 32: Pneumonia Therapeutics, Technology Trends Analytics Framework, Description, 2011 72

Figure 33: Pneumonia Therapeutics – Clinical Trials by Country, 2011 76

Figure 34: Pneumonia Therapeutics – Clinical Trials by Phase, 2011 78

Figure 35: Pneumonia Therapeutics – Clinical Trials by Status, 2011 79

Figure 36: Pneumonia Therapeutics – Overall Sponsors, 2011 81

Figure 37: Pneumonia Therapeutics - Prominent Sponsors, 2011 82

Figure 38: Pneumonia Therapeutics – Top Companies Participating in Clinical Trials, 2011 84

Figure 39: Implications for Future Market Competition in Pneumonia Therapeutics Market, 2011 86

Figure 40: Pneumonia Therapeutics Market – Clinical Pipeline by Company , 2011 88

Figure 41: GlobalData Market Forecasting Model 102Basilea Pharmaceutica Ltd.

Pfizer Inc.

To order this report:

Pathology Industry: Pneumonia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP)
2. Blue Cross and Blue Shield of Georgia Urges Seniors to Get Flu and Pneumonia Vaccines
3. Anthem Blue Cross and Blue Shield in Nevada Urges Seniors to Get Flu, Pneumonia Vaccines
4. Anthem Blue Cross and Blue Shield in Colorado Urges Seniors to Get Flu, Pneumonia Vaccines
5. American Lung Association Recognizes Older Adults Vaccination Day with Release of New Report Examining Disparities in Influenza and Pneumonia Vaccination Rates Among Older Americans
6. Activity Against Key Drug-Resistant Pathogens is the Most Important Attribute Influencing Surveyed Physicians Antibiotic Selection for Nosocomial Pneumonia in the U.S.
7. Advanced Life Sciences Submits Updated Special Protocol Assessment to FDA for Restanza in Community Acquired Bacterial Pneumonia
8. Patent Expiries of Blockbuster Antibiotics Will Fuel a Decline of More Than 15 Percent in the Community-Acquired Pneumonia Drug Market
9. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
10. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
11. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her ... would lash out at his family verbally and physically. , “When something upset him, he ... he would use it. He would throw rocks at my other children and say he ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):